CompletedNot Applicable

A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

United States110 participantsStarted 2021-04-09

Plain-language summary

The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the impact of transitioning from Xyrem to Xywav in a real-world setting.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female, aged 18 years or older
✓. Diagnosis of type 1 or type 2 narcolepsy by a physician
✓. Active prescription for Xyrem with a stable treatment regimen for at least 2 consecutive months
✓. Transitioning from Xyrem to Xywav within the next or past 7 days (- 7 days or + 7 days from the first dose of Xywav)
✓. Able to read and understand English
✓. Able to access to a computer/smart phone with internet connection
✓. Not currently a Jazz Pharmaceuticals employees or an immediate family member of a Jazz employee
✓. Willing and able to comply with the study schedule

What they're measuring

Number of Participants with Increased/Decreased/Same Dose Transitioning from Xyrem to Xywav

Timeframe: Baseline to 21 Weeks

Trial details

NCT IDNCT04803786

SponsorJazz Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-02-24

View on ClinicalTrials.gov More Narcolepsy trials